Indivior (INDV) CFO equity awards vest; shares withheld for taxes
Rhea-AI Filing Summary
Indivior Pharmaceuticals, Inc. Chief Financial Officer Ryan Preblick reported equity award activity involving performance stock units and common stock. In 2024, 204,904 shares vested from performance stock units granted on March 3, 2021 and were subject to a further two-year holding period. On March 3, 2026, this holding period ended and 87,597 shares were withheld to satisfy tax withholding obligations. On the same date, 86,949 shares of common stock vested from performance stock units granted on March 3, 2023 after performance conditions were determined to be met at 76.6% of a 113,510 share target. Each performance stock unit represents a contingent right to receive one share of common stock. After these transactions, Preblick held 317,292 shares of Indivior common stock directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Performance Stock Units | 113,510 | $0.00 | -- |
| Tax Withholding | Common Stock | 87,597 | $31.98 | $2.80M |
| Exercise | Common Stock | 86,949 | $0.00 | -- |
Footnotes (1)
- In 2024, 204,904 shares vested in respect of performance stock units granted to the Reporting Person on March 3, 2021. These shares were subject to a further two-year holding period. On March 3, 2026, the holding period ended and 87,597 shares were withheld to satisfy tax withholding obligations. Represents the vesting of performance stock units upon the determination that the performance conditions were met at 76.6% with respect to the performance stock units granted to the Reporting Person on March 3, 2023, of which 86,949 shares vested out of the 113,510 target amount. These shares will be released following a two-year holding period. Each performance stock unit represents a contingent right to receive one share of the Issuer's common stock.